Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PreMD cholesterol test

This article was originally published in The Gray Sheet

Executive Summary

Toronto-based PreMD files a 510(k) application seeking a broader claim for its Prevu POC noninvasive sterol test, the firm announces June 6. PreMD hopes the test, which measures cholesterol levels in the skin and was cleared in September for risk assessment of coronary artery disease in patients with a history of heart attack or evidence of artery blockage, will be cleared for patients without known or suspected disease. FDA is also reviewing a 510(k) application for Prevu LT, designed for use in the life insurance industry. Other cancer tests in development at PreMD include ColorectAlert, LungAlert and a breast cancer diagnostic...

You may also be interested in...



New Data Supports Broader Clearance For Skin Cholesterol Test, Maker Says

Non-invasive diagnostic test maker PreMD says it has the necessary data to support broader use of its PREVU POC skin cholesterol test in asymptomatic patients

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel